Asymmetrical Structure

Bispecific Antibodies (BsAb) exhibit poor manufacturability and challenging analytics

S-DUAL™ addresses these issues through its unique structure and properties

The Problem of BsAbs: Mispairings

• Standard BsAb - Desired BsAb
• 8 Possible BsAb Combinations - Probability of correct pairing: 1/8

Mispairings > Poor peak separation > Process & Analytical issues

• Similar physiochemical properties of mispaired BsAb result in difficult peak separation
• Challenging purification, analytics and poor productivity

S-DUAL™: Address BsAb Mispairings

S-DUAL™ BsAb Platform Structure

Asymmetric antibody structure, along with knob-and-holes at the CH3 regions, assures that only your desired BsAb is produced without mispairings.

S-DUAL™ platform expresses BsAb from a single cell line, reducing operational complexity.

Correctly Paired bsAb

Impurities are removed with ease through standard purification methods

• SEC-HPLC: Consistent purities in excess of 98%
• Reducing CE-SDS: Main peak is comprised of the expected ratio of LC/HC, demonstrating correct LC/HC pairing of intact BsAb

SEC-HPLC (%)

S-DUAL

• HMW
• Main
• LMW

(VEGF x HER2)

• 0.6
• 98.5
• 0.9

CE-SDS (%)

S-DUAL

• 1H1L
• 2H1L
• Main

(VEGF x HER2)

• 0.8
• 2.6
• 96.6

CE-SDS - After 3-step purification, Correct hetero-dimerization >96%

*CE-SDS : Capillary Electrophoresis Sodium Dodecyl Sulfate

SEC-HPLC - Transient expression, after 3-step purification, Monomer purity >98%

*SEC-HPLC : Size Exclusion-High-Performance Liquid Chromatography

Low Immunogenicity Risk

S-DUALTM consists of components derived from human immunoglobulin

In silico models support the low immunogenicity of BsAb resulting from the S-DUALTM platform

*In silico assessment of Immunogenicity : Performed by Abeza using their iTope™ and T Cell Epitope Database (TCED™) platform